Q3: How does CoverWell protect patients
TRIUMPH-4 Phase III: 28.7% weight loss at 68 weeks highest ever recorded.Retatrutide vs Semaglutide vs TirzepatideRetatrutide: 28.7% weight loss (68 wk) Triple agonist (GLP-1+GIP+GCGR)Tirzepatide (Mounjaro/Zepbound): 22.5% (72 wk) Dual agonist (GLP-1+GIP)Semaglutide (Wegovy/Ozempic): 15-17% (68 wk) GLP-1 onlyKey Clinical Results (April 2026)TRIUMPH-4 Phase III (Dec 2025): 28.7% body weight reduction, 71.2 lbs lost at 12mg doseTRANSCEND-T2D-1 (Mar 2026): 2.0% HbA1c reduction, 16.8% weight loss in type 2 diabetesPhase II (NEJM 2023): 24.2% weight loss at 48 weeks, no plateau observedFDA NDA submission: Q4 2026-Q1 2027Research-Grade RetatrutideBioInfinity Lab GLP3-R: 99%+ purity, third-party COA verified, GMP compliant
Snapin Mediates Incretin Action and Augments Glucose-dependent Insulin Secretion
But the details around that daily dose matter enormously for effectiveness
Almandoz JP, Wadden TA, Tewksbury C, et al
Think of foods you may gravitate to if you arent feeling great, such as steamed white rice, toast, or oatmeal